Clinical Trial Update: A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) [Phase 1, Phase 2]

View source ↗

Summary

A Phase I–II trial in Acute Myeloid Leukemia evaluating an all-oral combination of the menin inhibitor SNDX-5613 (revumenib) with decitabine/cedazuridine (ASTX7…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• ASTX727 (decitabine/cedazuridine) (decitabine/cedazuridine)
• Revumenib (SNDX-5613) (revumenib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING